Fig. 1 · Structure

Documents & Downloads

EPZ020411

Cat. No. A16377 CAS 1700663-41-7

PRMT6 inhibitor

EPZ020411 is a potent and selective inhibitor of PRMT6 with IC50 of 10 nM, has >10 fold selectivity for PRMT6 over PRMT1 and PRMT8.

In Stock

Publications for EPZ020411

1 publication citing this product

  1. Tianzhi Huang, .et al. , Mol Cell, 2021, Mar 18;81(6):1276-1291 PMID: 33539787

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

EPZ020411 inhibited PRMT6-associated methylation markers in glioblastoma stem-like cells. In GSC576 cells, RCC1me2 and H3R2me2 signals decreased with increasing concentration and exposure time, whereas the H4R3me2 signal was comparatively preserved. This cellular marker comparison does not establish exclusive target selectivity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PRMT6 IC50 0.01 μM
PRMT1 IC50 0.119 μM
PRMT8 IC50 0.223 μM

Cellular Effect

Cell Line Activity Value Description Reference
A-375 IC50 0.637 μM Inhibition of his-tagged PRMT6 (unknown origin) expressed in human A375 cells assessed as reduction in H3R2 methylation at 0.01 to 20 uM incubated for 48 hrs by Western blot method [PMID: 26101569]
A-375 IC50 7.1 μM Inhibition of PRMT1 in human A375 cells assessed as effect on monomethyl R*GG motif methylation at 0.01 to 20 uM incubated for 48 hrs by Western blot method [PMID: 26101569]

EPZ020411 Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of EPZ020411 from 1 published reference. In vitro models include patient-derived glioblastoma stem-like GSC576 cells; patient-derived glioblastoma stem-like GSC576 and GSC23 cells.

EPZ020411 In Vitro Studies

EPZ020411 reduced five-day viability in patient-derived GSC576 and GSC23 glioblastoma stem-like cells. The cellular viability IC50 values printed in Figure 7E were 24.75 μM and 28.91 μM, respectively. These endpoints are distinct from biochemical enzyme-inhibition potency. [1]

Cellular methylation response in GSC576

Cell-based study · Patient-derived glioblastoma stem-like GSC576 cells [1]

EPZ020411 reduced RCC1 R214me2 and H3R2me2 signals with increasing concentration and exposure time. The H4R3me2 signal was comparatively preserved, providing a limited substrate-marker comparison rather than proof of exclusive PRMT6 selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
RCC1me2 and H3R2me2 immunoblot signals, compared with H4R3me2 and total RCC1/H3qualitative response Reduced RCC1me2 and H3R2me2; H4R3me2 comparatively unchanged[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 5, 10, 20 and 50 μM for the concentration series; 20 μM for the time series
Exposure duration
12 h concentration series; 0, 4, 8, 12 and 24 h time series
Method
Cell exposure followed by immunoblot analysis
Reported limits
Panel A does not specify solvent concentration or blot replicate number; no biochemical IC50 is inferred from these cellular markers.
Methods and source locations

Compound reported in the paper: EPZ020411; Compound label in the paper: EPZ

Findings apply to the reported research reagent and models; no salt conversion or current AdooQ lot validation is inferred.

Figure 7A and caption P153; Results P28; Methods P46, P58; Key Resources Table

RCC1me2 and H3R2me2 immunoblot signals, compared with H4R3me2 and total RCC1/H3: Immunoblot; total RCC1 and histone H3 shown as protein controls. — Figure 7A; Results P28; STAR Methods Immunoblot Analysis (P58)

Five-day viability response in GSC576 and GSC23

Cell-based study · Patient-derived glioblastoma stem-like GSC576 and GSC23 cells [1]

Five-day EPZ020411 exposure decreased cell viability in both GSC models. Figure 7E labels cellular viability IC50 values of 24.75 μM for GSC576 and 28.91 μM for GSC23; these are not biochemical PRMT6 potencies.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
GSC576 viability after 5 dayscellular viability IC50 24.75 μM[1]
GSC23 viability after 5 dayscellular viability IC50 28.91 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 0.5, 1, 2, 5, 10, 20, 50 and 100 μM
Exposure duration
5 days
Method
Cell viability assay; values normalized to the zero-concentration control in Figure 7E
Reported limits
Solvent concentration and IC50 fitting procedure/uncertainty are not specified for Figure 7E. Methods n=4 does not establish four independent biological replicates. Grouped data are mean ± SEM.
Methods and source locations

Compound reported in the paper: EPZ020411; Compound label in the paper: EPZ

Findings apply to the reported research reagent and models; no salt conversion or current AdooQ lot validation is inferred.

Figure 7E; caption P157, P162; Results P28; Methods P46, P55, P77; Key Resources Table

GSC576 viability after 5 days: Figure-labelled IC50; shared viability methods describe CellTiter-Glow 2.0 and n=4 per condition/point. — Figure 7E left; caption P157; Methods P55

GSC23 viability after 5 days: Figure-labelled IC50; shared viability methods describe CellTiter-Glow 2.0 and n=4 per condition/point. — Figure 7E right; caption P157; Methods P55

EPZ020411 In Vivo Studies

In intracranial GSC576 and GSC23 xenografts, EPZ020411 (10 mg/kg subcutaneously daily for three weeks) combined with irradiation (2 Gy on five consecutive days) prolonged mouse survival relative to either monotherapy (n=5/group/model). Drug treatment began one day after transplantation and irradiation began one week after transplantation. The authors reported negligible body-weight changes, with data not shown; this does not establish general safety. [1]

EPZ020411 and radiotherapy in orthotopic GSC xenografts

Animal study · GSC576 and GSC23 intracranial xenografts in immunocompromised Ncr nu/nu mice [1]

The combination prolonged survival relative to EPZ020411 or irradiation alone in both xenograft models (n=5/group). This is combination evidence in immunocompromised mice. The authors report negligible body-weight effects for all therapies, but those data are not shown.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Survival of mice bearing GSC576 or GSC23 xenograftsKaplan–Meier survival comparison Combination survival longer than either monotherapy; n=5/group/model[1]

Conditions shared by the study groups

Vehicle
Saline, pH 6.5, in the control group; drug formulation otherwise unspecified
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Saline control
No EPZ020411
Randomized saline control, EPZ monotherapy, irradiation monotherapy and combination groupsReference survival curves and tumor bioluminescence.[1]
EPZ020411 alone
10 mg/kg
Randomized saline control, EPZ monotherapy, irradiation monotherapy and combination groupsMonotherapy comparator; combination survival exceeded this group. No exact single-agent survival effect size is asserted.[1]
Irradiation alone
2 Gy per irradiation treatment
Randomized saline control, EPZ monotherapy, irradiation monotherapy and combination groupsMonotherapy comparator; combination survival exceeded this group.[1]
EPZ020411 plus irradiation
EPZ020411 10 mg/kg plus irradiation 2 Gy per treatment
Randomized saline control, EPZ monotherapy, irradiation monotherapy and combination groupsLonger survival than either monotherapy in both GSC xenograft models; qualitative BLI supports reduced tumor burden.[1]
Saline control
Model: Intracranial GSC576 or GSC23 xenografts in 6–8-week-old immunocompromised Ncr nu/nu mice; n=5/group/model
Reported limits: No exact median survival or hazard ratio extracted; animal sex balance is stated for tumorigenicity studies but not separately confirmed for these therapeutic cohorts.
EPZ020411 alone
Model: Intracranial GSC576 or GSC23 xenografts in 6–8-week-old immunocompromised Ncr nu/nu mice; n=5/group/model
Route: Subcutaneous
Frequency: Daily
Treatment course: 3 weeks, starting 1 day after brain transplantation
Reported limits: No exact median survival or hazard ratio extracted; animal sex balance is stated for tumorigenicity studies but not separately confirmed for these therapeutic cohorts.
Irradiation alone
Model: Intracranial GSC576 or GSC23 xenografts in 6–8-week-old immunocompromised Ncr nu/nu mice; n=5/group/model
Route: Irradiation
Frequency: Five consecutive days
Treatment course: Starting 1 week after brain transplantation
Reported limits: No exact median survival or hazard ratio extracted; animal sex balance is stated for tumorigenicity studies but not separately confirmed for these therapeutic cohorts.
EPZ020411 plus irradiation
Model: Intracranial GSC576 or GSC23 xenografts in 6–8-week-old immunocompromised Ncr nu/nu mice; n=5/group/model
Route: Subcutaneous EPZ020411 plus irradiation
Frequency: EPZ020411 daily; irradiation on five consecutive days
Treatment course: EPZ020411 for 3 weeks starting day 1; irradiation starting 1 week after transplantation
Reported limits: No exact median survival or hazard ratio extracted; animal sex balance is stated for tumorigenicity studies but not separately confirmed for these therapeutic cohorts.
Methods and source locations

Compound reported in the paper: EPZ020411; Compound label in the paper: EPZ

Findings apply to the reported research reagent and models; no salt conversion or current AdooQ lot validation is inferred.

Figure 7I–J; Results P29; caption P160; Methods P43–44, P77; Key Resources Table

Survival of mice bearing GSC576 or GSC23 xenografts: Kaplan–Meier analysis with log-rank testing in shared statistical methods. No curve-derived median or exact P value reported here. — Figure 7I–J; Results P29; caption P160; Methods P77

Saline control · Figure 7I–J; caption P160; Methods Mice P43, Xenograft Studies P44

EPZ020411 alone · Figure 7I–J; caption P160; Methods Mice P43, Xenograft Studies P44

Irradiation alone · Figure 7I–J; caption P160; Methods Mice P43, Xenograft Studies P44

EPZ020411 plus irradiation · Figure 7I–J; caption P160; Methods Mice P43, Xenograft Studies P44

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1700663-41-7
Applications PRMT6 inhibitor
Formula C25H38N4O3
Molecular Weight 442.59
SMILES
CN(CC1=CNN=C1C2=CC=C(O[C@@H]3C[C@@H](OCCC4CCOCC4)C3)C=C2)CCNC

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

EPZ020411 Research References

  1. [1] Huang T, Yang Y, Song X, et al. PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. Molecular Cell (2021). PMID: 33539787 DOI: 10.1016/j.molcel.2021.01.015 Source material

Publications

1 publication citing this product

  1. Tianzhi Huang, .et al. , Mol Cell, 2021, Mar 18;81(6):1276-1291 PMID: 33539787

Added to your cart

View Cart Checkout
Loading...